ArticleMolecular therapy. Nucleic acids2025
The biochemical function of bivalent aptamer assemblies against B cell markers CD19 and CD20.
Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bivalent aptamer assemblies: A versatile toolkit for precision targeting of B-cell malignancies.Molecular therapy. Nucleic acids · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
B cells, essential components of the adaptive immune system, are central to the pathology of B cell malignancies and autoimmune disorders. These cells can be specifically targeted using ligands that recognize B cell surface receptors such as CD19 and CD20. Utilizing ligand-guided selection (LIGS), a variation of the systematic evolution of ligands by exponential enrichment (SELEX) method, we previously identified high-affinity, high-specificity aptamers targeting CD19 and CD20. In this study, we report the functional characterization of dimeric aptamer assemblies designed to target CD19 and CD20 on B cell lymphomas, reinforcing the potential of LIGS-derived aptamers as versatile tools for targeting cell surface receptors. Functional studies in CD21-negative B cells using the most optimized dimeric aptamers revealed that the dimeric CD19 aptamers were selectively internalized, imitating the behavior of anti-CD19 antibodies. Additionally, dimeric CD20 aptamers exhibited enhanced antigen binding compared to their monomeric counterparts, without inducing calcium release. These findings underscore the promise of LIGS-generated aptamers as cost-effective, stable, and precise therapeutic agents for B cell-associated malignancies such as diffuse large B cell lymphoma (DLBCL), advancing the development of aptamer-based synthetic therapeutics with strong clinical potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.